Full Press Release Details
MARLBOROUGH, Mass. , April 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of NxThera. The company developed the Rezūm ® system, a minimally invasive therapy ( MIT ) for patients with symptomatic benign prostatic hyperplasia (BPH). With the completion of the acquisition, NxThera will become part of the Boston Scientific Urology and Pelvic Health business.
"We are confident in the potential for this system to help patients with BPH and increase the number of men choosing MITs, because it offers long-term relief from symptoms without the side effects of medications," said Dave Pierce , executive vice president and president, MedSurg, Boston Scientific. "The minimally invasive therapy segment is the fastest growing category in the treatment of BPH and, as an office-based procedure, the Rezūm system is appealing to patients, clinicians and payers."
The Boston Scientific Urology and Pelvic Health business provides a range of treatment options for men's and women's urological and gynecological conditions. The Rezūm system complements the company's existing portfolio of treatment options for symptomatic BPH, which includes the GreenLight XPS TM Laser Therapy system and holmium laser platforms.
The two organizations announced a definitive agreement on March 21, 2018 for Boston Scientific to acquire NxThera.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACTS Media: Catherine Brady Boston Scientific Corporation 508-683-4797 (office) [email protected]
Investors: Susie Lisa , CFA Boston Scientific Corporation 508-683-5565 (office) [email protected]
SOURCE Boston Scientific Corporation